Novartis

NovartisNovartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world.

www.novartis.com

Novartis RSS Channel

Filters
List of articles in category Novartis
Title Published Date
Commitment of Novartis in advancing treatments for patients with cancer and rare diseases 02 December 2010
Novartis unveils long-term strategy to grow in a dynamically changing healthcare environment 18 November 2010
New data show potential for Novartis Meningitis B vaccine (4CMenB) candidate 04 November 2010
Novartis therapy Lucentis® recommended for approval in EU 25 October 2010
Novartis delivers excellent performance in third quarter 22 October 2010
Novartis affirms commitment to sustain efforts toward final elimination of leprosy 13 October 2010
Novartis announces agreement to develop influenza vaccines 08 October 2010
Novartis obtains CHMP positive opinion for its investigational pre-pandemic influenza vaccine Aflunov® 28 September 2010
Novartis announces Russian regulatory approval for Gilenya® 13 September 2010
Novartis delivers strong financial performance in second quarter 20 July 2010
Novartis gains new indication for Diovan®* for the treatment of children and adolescents 03 May 2010
Novartis receives approval in the European Union for Menveo® 22 March 2010
Novartis oral MS therapy FTY720 shows reduced risk of confirmed disability progression 25 January 2010
Novartis set to sustain its leading global position in oncology 10 December 2009
Novartis receives approval in the European Union for Onbrez® Breezhaler® 08 December 2009
Novartis receives regulatory approval in Germany for Celtura® 11 November 2009
Novartis announces USD 1 billion investment to build largest pharmaceutical R&D institute in China 04 November 2009
Novartis unveils Lab of Future concept to top European students at Biotechnology Leadership Camp (BioCamp) 27 August 2009
Afinitor® approved in EU as first treatment proven to benefit patients with advanced kidney cancer 10 August 2009
Novartis delivers strong operational performance in the first half of 2009 20 July 2009